Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 24, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
May 19, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces CEO Transition
March 25, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 05, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
February 14, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at February Investor Conferences
February 01, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
January 11, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 05, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
January 04, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
January 03, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
January 03, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
January 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at November Investor Conferences
November 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
October 30, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at October Investor Conferences
September 28, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Dyne Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Tickers
DYN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.